Table 2 The more significant studies describing the effect of CK2 inhibitors in combination with drugs in resistant cells and/or in in vivo models
From: Role of protein kinase CK2 in antitumor drug resistance
CK2 inhibitor | In combination with: | Tumor type | Resistance to: | In vivo study | REF |
|---|---|---|---|---|---|
BMS-595 BMS-211 | anti-CTLA-4 antibody | Lewis lung carcinoma, colon carcinoma, breast carcinoma | Â | Yes | [120] |
CGIB-300 | Cisplatin | Cervical cancer | Â | Yes | [75] |
CX-4945 | Cisplatin, carboplatin, gemcitabine | Ovarian cancer | Â | Yes | [73] |
CX-4945 | Imatinib | Chronic myeloid leukemia | Imatinib | Â | [17] |
CX-4945 | Vinblastin | T-lymphoblastic leukemia | MDR | Â | [60] |
CX-4945 | Decitabine | Acute B-lymphoblastic leukemia | Â | Yes | [121] |
CX-4945 | Gemcitabine/ cisplatin | Cholangiocarcinoma | Â | Yes | [55] |
CX-4945 | Paclitaxel | Gastric cancer | Paclitaxel | Yes | [18] |
CX-4945 | Temozolomide | Glioblastoma | Â | Yes | [122] |
CX-4945 | Fludarabine | Chronic lymphocytic leukemia | Fludarabine | Yes | [115] |
CX-4945 | Dabrafenib (BRAF inhibitor), erlotinib (EGFR) inhibitor) | Colon cancer | BRAF inhibitors | Â | [123] |
CX-4945 | gefitinib/erlotinib | Lung cancer | gefitinib/erlotinib | Â | [96] |
CX-4945 | MEK inhibitor AZD6244 | Non–small cell lung cancer | EGFR inhibitor |  | [99] |
CX-5011 | Imatinib, MEK inhibitor U0126 | Chronic myeloid leukemia | Imatinib | Â | [16] |
DRB | Doxorubicin | Cervical cancer | Â | Yes | [19] |
DRB, apigenin, emodin | TRAIL Anti-Fas | Endometrial carcinoma | TRAIL | Â | [23] |
Quinalizarin | Ionizing radiation | Lung cancer | Â | Yes | [124] |
Quinalizarin | Pim-1 inhibitor TCS | T-lymphoblastic leukemia | MDR | Â | [119] |
TBB | Imatinib | Chronic myeloid leukemia | Imatinib | Â | [85] |
TBB/IQA/2a | Vinblastin | T-lymphoblastic leukemia | MDR | Â | [58] |
tTBB (also known as TBBz) | HSP90 inhibitor 17-AAG | Multiple myeloma | Â | Yes | [125] |